​

Athira Pharma (ATHA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ATHA Stock Forecast

Athira Pharma (ATHA) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $4.00 and a low of $4.00. This represents a -5.44% decline from the last price of $4.23.

- $1 $2 $3 $4 $5 High: $4 Avg: $4 Low: $4 Last Closed Price: $4.23

ATHA Stock Rating

Athira Pharma stock's rating consensus is Hold, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (14.29%), 6 Hold (85.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 7 0 6 1 Strong Sell Sell Hold Buy Strong Buy

ATHA Price Target Upside V Benchmarks

TypeNameUpside
StockAthira Pharma-5.44%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$4.00$4.00
Last Closing Price$4.23$4.23$4.23
Upside/Downside--5.44%-5.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25--2--2
Sep, 25--2--2
Aug, 25--2--2
Jul, 25--3--3
Jun, 25--3--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 19, 2025Graig SuvannavejhMizuho Securities$4.00$3.834.44%-5.44%
Jun 22, 2022Andrew TsaiJefferies$3.00$2.855.26%-29.08%
Apr 21, 2022Berenberg Bank$33.00$11.63183.75%680.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2024Rodman & RenshawBuyNeutraldowngrade
Sep 04, 2024JMP SecuritiesPerformMarket Performdowngrade
Sep 04, 2024JMP SecuritiesMarket OutperformPerformdowngrade
Sep 04, 2024BTIGNeutralPositivedowngrade
Sep 03, 2024BTIGNeutraldowngrade
Aug 19, 2024Rodman & RenshawBuyinitialise
Oct 17, 2022JMP SecuritiesMarket Outperformupgrade
Jun 22, 2022JefferiesBuydowngrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.10$-2.52----
Avg Forecast$-3.18$-2.42$-1.51$-0.82$-0.84$-1.44
High Forecast$-3.11$-2.42$-1.51$-0.81$-0.80$-1.44
Low Forecast$-3.25$-2.42$-1.51$-0.82$-0.88$-1.44
Surprise %-2.52%4.13%----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$13.43M--
High Forecast---$13.43M--
Low Forecast---$13.43M--
Surprise %------

Net Income Forecast

$-125M $-106M $-87M $-68M $-49M $-30M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.67M$-96.94M----
Avg Forecast$-120.87M$-92.10M$-57.41M$-30.99M$-31.94M$-54.75M
High Forecast$-118.33M$-92.10M$-57.41M$-30.80M$-30.55M$-54.75M
Low Forecast$-123.41M$-92.10M$-57.41M$-31.18M$-33.33M$-54.75M
Surprise %-2.65%5.25%----

ATHA Forecast FAQ

Is Athira Pharma stock a buy?

Athira Pharma stock has a consensus rating of Hold, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Athira Pharma is a neutral investment for most analysts.

What is Athira Pharma's price target?

Athira Pharma's price target, set by 7 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $4 at the low end to $4 at the high end, suggesting a potential -5.44% change from the previous closing price of $4.23.

How does Athira Pharma stock forecast compare to its benchmarks?

Athira Pharma's stock forecast shows a -5.44% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Athira Pharma over the past three months?

  • October 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Athira Pharma’s EPS forecast?

Athira Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.51, marking a -40.08% decrease from the reported $-2.52 in 2024. Estimates for the following years are $-0.82 in 2026, $-0.84 in 2027, and $-1.44 in 2028.

What is Athira Pharma’s revenue forecast?

Athira Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $13.43M, followed by $0 for 2027, and $0 for 2028.

What is Athira Pharma’s net income forecast?

Athira Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-57.41M, representing a -40.78% decrease from the reported $-96.94M in 2024. Projections indicate $-30.986M in 2026, $-31.937M in 2027, and $-54.749M in 2028.